We do what can’t be done:
Leverage AI to predict clinical trial outcomes
A biopharmaceutical company spends about $2.5 billion on developing a drug. With only 10-15% of drug candidates making through the clinical trial phase to approval, the company’s stock performance depends heavily on the outcome of its pipeline. Prior knowledge of approval probability of a trial can help investors gain an edge!
So, is it possible to predict the result beforehand? At Innoplexus, it is!
Innoplexus harnesses machine learning technology to predict the success of clinical trials. Now, you can determine the likelihood of a drug passing a clinical trial phase based on several factors such as trial design, targeted patient population and the drug’s pharmacodynamic & pharmacokinetic properties. We also leverage external world data such as sponsor track record, investigator reputation and research trends by therapeutic area to accurately predict the trial success.
Unlock previously impossible opportunities using our insights to empower your investment strategy in the biopharmaceutical industry.
